NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Biological: Nivolumab

First Posted Date: 2017-12-26

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT03382561

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 773 locations

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Early Phase 1

Terminated

Conditions: Ovarian Carcinoma

Interventions: Biological: Denosumab
Procedure: Salpingo-Oophorectomy

First Posted Date: 2017-12-26

Last Posted Date: 2022-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT03382574

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel

and more 3 locations

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Phase 2

Withdrawn

Conditions: Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Positive
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Fulvestrant
Drug: Copanlisib
Other: Laboratory Biomarker Analysis
Drug: Palbociclib

First Posted Date: 2017-12-19

Last Posted Date: 2018-08-14

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03377101

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3

Active, not recruiting

Conditions: Carcinoid Tumor
Functioning Pancreatic Neuroendocrine Tumor
Intermediate Grade Lung Neuroendocrine Neoplasm
Locally Advanced Digestive System Neuroendocrine Neoplasm
Locally Advanced Digestive System Neuroendocrine Tumor G1
Locally Advanced Lung Neuroendocrine Neoplasm
Locally Advanced Pancreatic Neuroendocrine Tumor
Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
Low Grade Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Placebo Administration
Other: Quality-of-Life Assessment
Procedure: X-Ray Imaging

First Posted Date: 2017-12-18

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 298

Registration Number: NCT03375320

Locations: 🇺🇸
Kaiser Permanente-Fresno, Fresno, California, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States

and more 432 locations

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Phase 2

Recruiting

Conditions: Metastatic Bladder Carcinoma
Advanced Bladder Carcinoma
Metastatic Genitourinary System Carcinoma
Advanced Genitourinary System Carcinoma
Stage III Bladder Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Procedure: Positron Emission Tomography

First Posted Date: 2017-12-18

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT03375307

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
UC San Diego Health System - Encinitas, Encinitas, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 14 locations

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Recruiting

Conditions: Adrenal Gland Neoplasm
Bone Diseases, Metabolic
Cardiovascular Disease
Hypertension
Hyperinsulinemia

First Posted Date: 2017-12-15

Last Posted Date: 2025-06-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1150

Registration Number: NCT03374215

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Endometrial Carcinoma
Metastatic Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2017-12-11

Last Posted Date: 2025-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT03367741

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 31 locations

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Colorectal Cancer With Hepatic Metastases
Liver Metastases
Colorectal Adenocarcinoma
Colorectal Carcinoma

Interventions: Device: Codman 3000 constant flow pump catheter
Drug: Panitumumab
Drug: FUDR-Dex
Drug: Oxaliplatin
Drug: 5FU
Drug: Irinotecan
Procedure: HAIP installation
Drug: cetuximab
Device: Medtronic SynchroMed II Pump

First Posted Date: 2017-12-08

Last Posted Date: 2025-04-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT03366155

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Neoplasms

Interventions: Drug: aza-TdC

First Posted Date: 2017-12-08

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT03366116

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Malignant Solid Neoplasm
Recurrent Lung Small Cell Carcinoma
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Stage IIIA Lung Small Cell Carcinoma AJCC v7
Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7
Stage IIIB Lung Small Cell Carcinoma AJCC v7
Stage IV Lung Small Cell Carcinoma AJCC v7
Unresectable Solid Neoplasm

Interventions: Biological: Navitoclax
Drug: Vistusertib

First Posted Date: 2017-12-08

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT03366103

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 11 locations

Home Terms & Conditions Privacy Policy